The report One Million Lives Saved Per Year: A Cost–Benefit Analysis of the Global Plan to End Tuberculosis, 2023–2030 and Beyond, published in the Journal of Benefit-Cost Analysis, evaluates the economic and health impacts of scaling up global efforts to combat tuberculosis (TB). Using the Global Plan to End TB as a framework, the analysis estimates a remarkable benefit-cost ratio (BCR) of 46, indicating that every dollar invested yields $46 in returns. Even under alternative scenarios, BCRs remain robust, ranging from 28 to 84.
The report highlights the potential to save 27.3 million lives between 2023 and 2050, averaging nearly one million averted deaths annually, with an average cost of $2,000 per life saved. It underscores TB interventions as highly cost-effective, combining existing tools with innovative technologies such as new vaccines and digital adherence systems. The findings position TB spending as a critical investment for achieving global health and sustainable development goals.